We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+43.59%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
+$149M
Cap. Flow
-$99M
Cap. Flow %
-9.49%
Top 10 Hldgs %
81.6%
Holding
33
New
2
Increased
4
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$56.8M
2
RVMD icon
Revolution Medicines
RVMD
+$26.7M
3
ANNX icon
Annexon
ANNX
+$5.84M
4
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$2.14M
5
XFOR icon
X4 Pharmaceuticals
XFOR
+$774K

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$71.2M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.9M
3
EQRX
EQRx, Inc. Common Stock
EQRX
+$22.2M
4
PHVS icon
Pharvaris
PHVS
+$17.8M
5
NTRA icon
Natera
NTRA
+$15M

Sector Composition

Rank Sector Weight
1 Healthcare 98.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLO icon
26
Xilio Therapeutics
XLO
$59.5M
$1.54M 0.15%
200,387
– –
NAMSW icon
27
NewAmsterdam Pharma Warrant
NAMSW
$78.2M
$313K 0.03%
100,000
– –
CRNX icon
28
Crinetics Pharmaceuticals
CRNX
$8.96B
– –
-1,275,552
Closed -$37.9M
DVAX
29
DELISTED
Dynavax Technologies
DVAX
– –
-915,000
Closed -$13.5M
SWTX
30
DELISTED
SpringWorks Therapeutics
SWTX
– –
-3,081,307
Closed -$71.2M
TVRD
31
Tvardi Therapeutics
TVRD
$22.1M
– –
-657
Closed -$39.7K
CBAY
32
DELISTED
Cymabay Therapeutics
CBAY
– –
-913,969
Closed -$13.6M
EQRX
33
DELISTED
EQRx, Inc. Common Stock
EQRX
– –
-10,003,573
Closed -$22.2M
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q4 2023 Portfolio in Review

As of Q4 2023, Bain Capital Life Sciences Investors held 33 positions worth $1.04B, up 17% from $894M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $99M in Q4 2023, closing 6 positions and reducing 3 holdings. Its most notable exit was SpringWorks Therapeutics, an estimated $71.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.

Against the trend, Bain Capital Life Sciences Investors opened a new position in Madrigal Pharmaceuticals worth $75.1M.

  • Bain Capital Life Sciences Investors's largest Q4 2023 buy was Madrigal Pharmaceuticals: 324,619 shares worth $75.1M.
  • Bain Capital Life Sciences Investors added most to Annexon in Q4 2023, an estimated $5.84M increase.
  • Bain Capital Life Sciences Investors's biggest Q4 2023 reduction was Pharvaris, cutting an estimated $17.8M.
  • Bain Capital Life Sciences Investors fully exited SpringWorks Therapeutics in Q4 2023, selling an estimated $71.2M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 82% of its $1.04B portfolio in Q4 2023.
  • Bain Capital Life Sciences Investors opened 2 new positions and closed 6 in Q4 2023.
  • Bain Capital Life Sciences Investors's portfolio value rose 17% quarter-over-quarter to $1.04B.

Based on Bain Capital Life Sciences Investors's 13F filing for Q4 2023, filed 13 Feb 2024.